Why Protalix BioTherapeutics (PLX) Stock Is Surging Today

NEW YORK (TheStreet) -- Protalix BioTherapeutics  (PLX) surged Thursday after the company co-announced with Pfizer (PFE) that the FDA had approved the expansion of ELELYSO for injection in pediatric patients.

The expansion means the drug is now indicated for long-term enzyme replacement therapy, or ERT, for both adult and pediatric patients who have been diagnosed with Type 1 Gaucher disease.

Type 1 is the most common form of the inherited disease, which causes enlargement of the liver and spleen, anemia, decline in blood platelets leading to bruising, lung disease, and bone problems such as pain, fractures and arthritis.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Protalix was up 13.69% to $2.74 at 2:45 p.m.

PLX Chart PLX data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Trump, Trade Wars, General Electric, 'Jurassic World' - 5 Things You Must Know

Trump, Trade Wars, General Electric, 'Jurassic World' - 5 Things You Must Know

Stocks Weaken Around The World as Trump Opens New Fronts in Global Trade War

Stocks Weaken Around The World as Trump Opens New Fronts in Global Trade War

Trump Puts Tech in Trade War Crosshairs With Planned Curb on China Investment

Trump Puts Tech in Trade War Crosshairs With Planned Curb on China Investment

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come